If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, ...

Cogstate Ltd ( ($AU:CGS) ) just unveiled an announcement. Cogstate has disclosed a change in director Kim Wenn’s beneficial interest in the ...

Cogstate Ltd ( ($AU:CGS) ) has issued an announcement. Cogstate Ltd has applied to the ASX for quotation of 110,000 additional ordinary fully paid ...

Quite a few insiders have dramatically grown their holdings in Cogstate Limited (ASX:CGS) over the past 12 months. An insider's optimism about the company's prospects is a positive sign. While we ...

The company is also eyeing wider work with other dementia-related trials, as well as studies for Parkinson’s disease, psychiatry, schizophrenia, sleep disorders and rare diseases. “Cogstate’s future ...

Cogstate Ltd. Cogstate Ltd. is a global cognitive science company, which engages in delivering software services to optimize the measurement of cognition in clinical trials, academic research, ...

As of November 9, 2025, the average one-year price target for Cogstate is $1.51/share. The forecasts range from a low of $1.50 to a high of $1.56. The average price target represents an increase of ...

Cogstate Ltd ( (AU:CGS) ) just unveiled an announcement.

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things, we'll want to see two things; firstly, a growing return on capital employed ...

The average one-year price target for Cogstate (OTCPK:COGZF) has been revised to $1.94 / share. This is an increase of 28.02% from the prior estimate of $1.51 dated November 9, 2025. The price target ...

BOSTON--(BUSINESS WIRE)--The cognitive science company, Cogstate, today announced that its Healthcare Division has received CE Mark approval for its Cognigram TM digital cognitive assessment system.

Cogstate Ltd. Annual stock financials by MarketWatch. View the latest COGZF financial statements, income statements and financial ratios.